kongenital nephrogenic diabetes insipidusに起因する遺伝子の分子識別
W Rosenthal1, A Seibold, A Antaramian
1Department of Cell Biology, Baylor College of Medicine, Houston, Texas 77030.
Nature
|September 17, 1992
まとめ
kongenital nephrogenic diabetes insipidus (CNDI) は,V2受容体遺伝子の変異によって引き起こされる. 研究者らは,罹患した男性のV2受容体遺伝子の欠失とコドン変化を特定し,抗利尿ホルモンに対する腎臓の無反応を説明した.
科学分野:
- 分子生物学は分子生物学である.
- 遺伝学 遺伝学とは
- ネフロロジーはネフロロジーを用います.
背景:
- 抗利尿ホルモン (アルギニンバソプレシン) は,腎臓の採集管内のV2受容体を通して水の再吸収を調節する.
- kongenital nephrogenic diabetes insipidus (CNDI) は,アルギニン・バソプレシンに対する腎臓の抵抗によって特徴づけられるX関連疾患である.
- V2受容体の活性化により,集水管の水浸透性を高める信号経路が誘発されます.
研究 の 目的:
- 罹患家族における先天性腎臓発作性糖尿病不発症 (CNDI) の遺伝的基礎を調査する.
- CNDIの原因となるV2受容体遺伝子の変異を特定する.
- 特定のV2受容体遺伝子変異を疾患のフェノタイプと相関させるため.
主な方法:
- 感染した男性とその家族におけるV2受容体遺伝子の遺伝子解析.
- V2受容体遺伝子の変異を特定するためにDNAの配列決定.
- 遺伝子削除,フレームシフト,コドン変化の分析.
主要な成果:
- フレームシフトとV2受容体遺伝子の早期終結を引き起こす欠失は,CNDIの1人の患者で特定されました.
- 異なった変異,第3トランスメブラン領域のコドン変化が,別のCNDI患者で発見されました.
- 罹患した雄は変異したV2受容体アレルを持ち,無病の兄弟は正常なアレルを持ちました.
結論:
- V2受容体遺伝子の変異は,先天性 nefrogenic 糖尿病 insipidus (CNDI) の原因である.
- 欠損やコドン変化を含む特定の変異は,V2受容体の機能を破壊し,水の再吸収が低下する.
- V2受容体遺伝子の遺伝分析は,CNDIの診断に不可欠です.
関連する概念動画
02:59Animal Mitochondrial Genetics
Among all the organelles in an animal cell, only mitochondria have their own independent genomes. Animal mitochondrial DNA is a double-stranded, closed-circular molecule with around 20,000 base pairs. Mitochondrial DNA is unique in that one of its two strands, the heavy, or H, -strand is guanine rich, whereas the complementary strand is cytosine rich and called the light, or L, -strand. Compared to nuclear DNA, mitochondrial DNA has a very low percentage of non-coding regions and is marked by...
01:43Incomplete Dominance
Gregor Mendel's work (1822 - 1884) was primarily focused on pea plants. Through his initial experiments, he determined that every gene in a diploid cell has two variants called alleles inherited from each parent. He suggested that amongst these two alleles, one allele is dominant in character and the other recessive. The combination of alleles determines the phenotype of a gene in an organism.
01:05Single Nucleotide Polymorphisms-SNPs
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
01:27Glucose Transporters
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
01:20Inborn Errors of Metabolism
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...